Rxcurve
HCPCS Q5148 · per 1 MCG

Inj, nyposi 1 mcg

Products billed under this code include Nypozi.

Payment limit per 1 MCG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under Q5148

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Nypozi Cipla USA, Inc. 69097-0429-67 480 $492.48
Nypozi Cipla USA, Inc. 69097-0429-96 4800 $4,924.80
Nypozi Cipla USA, Inc. 69097-0430-67 300 $307.80
Nypozi Cipla USA, Inc. 69097-0430-96 3000 $3,078.00
Nypozi Tanvex BioPharma USA, Inc. 72374-0101-01 300 $307.80
Nypozi Tanvex BioPharma USA, Inc. 72374-0101-10 3000 $3,078.00
Nypozi Tanvex BioPharma USA, Inc. 72374-0102-01 480 $492.48
Nypozi Tanvex BioPharma USA, Inc. 72374-0102-10 4800 $4,924.80

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $1.026 −$0.008 1 MCG Inj, nyposi 1 mcg v1, posted September 17, 2026
3Q26 $1.034 +$0.006 1 MCG Inj, nyposi 1 mcg v1, posted September 15, 2026
2Q26 $1.028 +$0.031 1 MCG Inj, nyposi 1 mcg v1, posted September 15, 2026
1Q26 $0.997 – 1 MCG Inj, nyposi 1 mcg v1, posted September 15, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files